Strong future forecast for Eisai and Biogen's lecanemab in Alzheimer's disease
News that Eisai (TYO: 4523) and Biogen’s (Nasdaq: BIIB) anti-amyloid beta (Aβ) monoclonal antibody (MAb) lecanemab was effective in reducing cognitive clinical decline among patients with early Alzheimer’s disease (AD) in the Phase III Clarity AD trial (NCT03887455), resulted in a positive market reaction.
Biogen jumped by as much as 44% and Eisai climbed 17%.
The prospects for lecanemab were further endorsed by a report from analytics firm GlobalData, whose senior neurology analyst Pippa Salter noted that, after multiple failures, and the controversial approval and messy launch of Biogen’s anti-Aβ MAb Aduhelm (aducanumab), lecanemab has finally demonstrated in a large-scale pivotal trial that targeting Aβ can be a successful way to treat AD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze